{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:06:17Z","timestamp":1792605977835,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060026"],"award-info":[{"award-number":["82060026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170168"],"award-info":[{"award-number":["82170168"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The tumor microenvironment (TME) is a supportive environment responsible for promoting the growth and proliferation of tumor cells. Current studies have revealed that the bone marrow mesenchymal stem cells (BM-MSCs), a type of crucial stromal cells in the TME, can promote the malignant progression of tumors. However, in the adult B-cell acute lymphoblastic leukemia (B-ALL) microenvironment, it is still uncertain what changes in BM-MSCs are induced by leukemia cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we mimicked the leukemia microenvironment by constructing a BM-MSC\u2013leukemia cell co-culture system. In vitro cell experiments, in vivo mouse model experiments, lentiviral transfection and transcriptome sequencing analysis were used to investigate the possible change of BM-MSCs in the leukemia niche and the potential factors in BM-MSCs that promote the progression of leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the leukemia niche, the leukemia cells reduced the MSCs' capacity to\u00a0differentiate towards adipogenic and osteogenic subtypes, which also promoted the senescence and cell cycle arrest of the MSCs. Meanwhile, compared to the mono-cultured MSCs, the gene expression profiles of MSCs in the leukemia niche changed significantly. These differential genes were enriched for cell cycle, cell differentiation, DNA replication, as well as some tumor-promoting biofunctions including protein phosphorylation, cell migration and angiogenesis. Further, interferon alpha-inducible protein 6 (IFI6), as a gene activated by interferon, was highly expressed in leukemia niche MSCs. The leukemia cell multiplication was facilitated evidently by IFI6 both in vitro and in vivo. Mechanistically, IFI6 might promote leukemia cell proliferation by stimulating SDF-1\/CXCR4 axis, which leads to the initiation of downstream ERK signaling pathway. As suggested by further RNA sequencing analysis, the high IFI6 level in MSCs somewhat influenced the gene expression profile and biological functions of leukemia cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BM-MSCs in the leukemia niche have varying degrees of changes in biological characteristics and gene expression profiles. Overexpression of IFI6 in BM-MSCs could be a key factor in promoting the proliferation of B-ALL cells, and this effect might be exerted through the SDF-1\/CXCR4\/ERK signal stimulation. Targeting IFI6 or related signaling pathways might be an important measure to reduce the leukemia cell proliferation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-04464-1","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:02:24Z","timestamp":1693897344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["BM-MSCs display altered gene expression profiles in B-cell acute lymphoblastic leukemia niches and exert pro-proliferative effects via overexpression of IFI6"],"prefix":"10.1186","volume":"21","author":[{"given":"Chengyun","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-8087","authenticated-orcid":false,"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"2","key":"4464_CR1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.29271\/jcpsp.2018.02.118","volume":"28","author":"A Vallacha","year":"2018","unstructured":"Vallacha A, Haider G, Raja W, Kumar D. Remission rate of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA). J Coll Physicians Surg Pak. 2018;28(2):118\u201321.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"1","key":"4464_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s43046-021-00064-6","volume":"33","author":"HEA Elashtokhy","year":"2021","unstructured":"Elashtokhy HEA, Elgohary HE, Eldeep BB, Gaber SM, Elbedewy TA. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience. J Egypt Natl Canc Inst. 2021;33(1):9.","journal-title":"J Egypt Natl Canc Inst"},{"key":"4464_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/BLCTT.S170351","volume":"8","author":"M Hefazi","year":"2018","unstructured":"Hefazi M, Litzow MR. Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood Lymphat Cancer. 2018;8:47\u201361.","journal-title":"Blood Lymphat Cancer"},{"issue":"4","key":"4464_CR4","first-page":"266","volume":"15","author":"M Yilmaz","year":"2017","unstructured":"Yilmaz M, Kantarjian H, Jabbour E. Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol. 2017;15(4):266\u201374.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"16","key":"4464_CR5","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"issue":"2","key":"4464_CR6","doi-asserted-by":"crossref","first-page":"188585","DOI":"10.1016\/j.bbcan.2021.188585","volume":"1876","author":"S Kumari","year":"2021","unstructured":"Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P. Combinatorial therapy in tumor microenvironment: where do we stand? Biochim Biophys Acta Rev Cancer. 2021;1876(2):188585.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4464_CR7","doi-asserted-by":"crossref","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"4464_CR8","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.3390\/ijms22094426","volume":"22","author":"E Dander","year":"2021","unstructured":"Dander E, Palmi C, D\u2019Amico G, Cazzaniga G. The bone marrow niche in B-Cell acute lymphoblastic leukemia: the role of microenvironment from pre-leukemia to overt leukemia. Int J Mol Sci. 2021;22(9):4426.","journal-title":"Int J Mol Sci"},{"key":"4464_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.actbio.2019.09.009","volume":"101","author":"S Thakkar","year":"2020","unstructured":"Thakkar S, Sharma D, Kalia K, Tekade RK. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review. Acta Biomater. 2020;101:43\u201368.","journal-title":"Acta Biomater"},{"issue":"8","key":"4464_CR10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/stmcls\/sxac036","volume":"40","author":"L Frisbie","year":"2022","unstructured":"Frisbie L, Buckanovich RJ, Coffman L. Carcinoma associated mesenchymal stem\/stromal cells\u2014architects of the pro-tumorigenic tumor microenvironment. Stem Cells. 2022;40(8):705\u201315.","journal-title":"Stem Cells"},{"issue":"4","key":"4464_CR11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2018.214379","volume":"105","author":"L Boutin","year":"2020","unstructured":"Boutin L, Arnautou P, Trignol A, S\u00e9got A, Farge T, Desterke C, et al. Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through side population functionality and ABC transporter activation. Haematologica. 2020;105(4):987\u20139998.","journal-title":"Haematologica"},{"key":"4464_CR12","doi-asserted-by":"crossref","first-page":"708513","DOI":"10.3389\/fcell.2021.708513","volume":"9","author":"C Pan","year":"2021","unstructured":"Pan C, Fang Q, Liu P, Ma D, Cao S, Zhang L, et al. Mesenchymal stem cells with cancer-associated fibroblast-like phenotype stimulate SDF-1\/CXCR4 axis to enhance the growth and invasion of B-Cell acute lymphoblastic leukemia cells through cell-to-cell communication. Front Cell Dev Biol. 2021;9:708513.","journal-title":"Front Cell Dev Biol"},{"key":"4464_CR13","doi-asserted-by":"crossref","first-page":"3864948","DOI":"10.1155\/2019\/3864948","volume":"2019","author":"X Bonilla","year":"2019","unstructured":"Bonilla X, Vanegas NP, Vernot JP. Acute leukemia induces senescence and impaired osteogenic differentiation in mesenchymal stem cells endowing leukemic cells with functional advantages. Stem Cells Int. 2019;2019:3864948.","journal-title":"Stem Cells Int"},{"issue":"15","key":"4464_CR14","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.3390\/ijms22158166","volume":"22","author":"NP Vanegas","year":"2021","unstructured":"Vanegas NP, Ruiz-Aparicio PF, Uribe GI, Linares-Ballesteros A, Vernot JP. Leukemia-induced cellular senescence and stemness alterations in mesenchymal stem cells are reversible upon withdrawal of B-Cell acute lymphoblastic leukemia cells. Int J Mol Sci. 2021;22(15):8166.","journal-title":"Int J Mol Sci"},{"key":"4464_CR15","doi-asserted-by":"crossref","first-page":"677697","DOI":"10.3389\/fcell.2021.677697","volume":"9","author":"H Zhao","year":"2021","unstructured":"Zhao H, Li Z, Gao Y, Li J, Zhao X, Yue W. Single-cell RNA-sequencing portraying functional diversity and clinical implications of IFI6 in ovarian cancer. Front Cell Dev Biol. 2021;9:677697.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"4464_CR16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00262-004-0645-2","volume":"54","author":"E Tahara","year":"2005","unstructured":"Tahara E, Tahara H, Kanno M, Naka K, Takeda Y, Matsuzaki T, et al. G1P3, an interferon inducible gene 6\u201316, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother. 2005;54(8):729\u201340.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4464_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13046-020-01646-3","volume":"39","author":"Z Liu","year":"2020","unstructured":"Liu Z, Gu S, Lu T, Wu K, Li L, Dong C, et al. IFI6 depletion inhibits esophageal squamous cell carcinoma progression through reactive oxygen species accumulation via mitochondrial dysfunction and endoplasmic reticulum stress. J Exp Clin Cancer Res. 2020;39(1):144.","journal-title":"J Exp Clin Cancer Res"},{"key":"4464_CR18","doi-asserted-by":"crossref","first-page":"110610","DOI":"10.1016\/j.biopha.2020.110610","volume":"130","author":"C Pan","year":"2020","unstructured":"Pan C, Liu P, Ma D, Zhang S, Ni M, Fang Q, et al. Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia. Biomed Pharmacother. 2020;130:110610.","journal-title":"Biomed Pharmacother"},{"key":"4464_CR19","doi-asserted-by":"crossref","first-page":"811144","DOI":"10.3389\/fimmu.2022.811144","volume":"13","author":"T Menter","year":"2022","unstructured":"Menter T, Tzankov A. Tumor microenvironment in acute myeloid leukemia: adjusting niches. Front Immunol. 2022;13:811144.","journal-title":"Front Immunol"},{"issue":"2","key":"4464_CR20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4161\/cbt.11.2.14623","volume":"11","author":"W Zhang","year":"2011","unstructured":"Zhang W, Huang P. Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol Ther. 2011;11(2):150\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"4464_CR21","first-page":"1164","volume":"2","author":"LK Meyer","year":"2019","unstructured":"Meyer LK, Hermiston ML. The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia. Cancer Drug Resist. 2019;2(4):1164\u201377.","journal-title":"Cancer Drug Resist"},{"issue":"14","key":"4464_CR22","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/cancers14143303","volume":"14","author":"A Fallati","year":"2022","unstructured":"Fallati A, Di Marzo N, D\u2019Amico G, Dander E. Mesenchymal Stromal Cells (MSCs): an ally of B-Cell Acute Lymphoblastic Leukemia (B-ALL) cells in disease maintenance and progression within the bone marrow hematopoietic niche. Cancers (Basel). 2022;14(14):3303.","journal-title":"Cancers (Basel)"},{"key":"4464_CR23","doi-asserted-by":"crossref","first-page":"857045","DOI":"10.3389\/fcell.2022.857045","volume":"10","author":"Z Tan","year":"2022","unstructured":"Tan Z, Kan C, Wong M, Sun M, Liu Y, Yang F, et al. Regulation of malignant myeloid leukemia by mesenchymal stem cells. Front Cell Dev Biol. 2022;10:857045.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4464_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13287-021-02444-0","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chi Y, Wei Y, Zhang W, Wang F, Zhang L, et al. Bone marrow-derived mesenchymal stem\/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality. Stem Cell Res Ther. 2021;12(1):365.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"4464_CR25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/scd.2007.0008","volume":"16","author":"ZG Zhao","year":"2007","unstructured":"Zhao ZG, Liang Y, Li K, Li WM, Li QB, Chen ZC, et al. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev. 2007;16(4):637\u201348.","journal-title":"Stem Cells Dev"},{"issue":"1","key":"4464_CR26","doi-asserted-by":"crossref","first-page":"e84496","DOI":"10.1371\/journal.pone.0084496","volume":"9","author":"\u00c1 Vicente L\u00f3pez","year":"2014","unstructured":"Vicente L\u00f3pez \u00c1, V\u00e1zquez Garc\u00eda MN, Melen GJ, Entrena Mart\u00ednez A, Cubillo Moreno I, Garc\u00eda-Castro J, et al. Mesenchymal stromal cells derived from the bone marrow of acute lymphoblastic leukemia patients show altered BMP4 production: correlations with the course of disease. PLoS ONE. 2014;9(1):e84496.","journal-title":"PLoS ONE"},{"key":"4464_CR27","first-page":"1","volume":"2015","author":"GC Yang","year":"2015","unstructured":"Yang GC, Xu YH, Chen HX, Wang XJ. Acute lymphoblastic leukemia cells inhibit the differentiation of bone mesenchymal stem cells into osteoblasts in vitro by activating notch signaling. Stem Cells Int. 2015;2015:1\u201311.","journal-title":"Stem Cells Int"},{"issue":"10","key":"4464_CR28","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1507\/endocrj.EJ21-0005","volume":"68","author":"T Yuan","year":"2021","unstructured":"Yuan T, Shi C, Xu W, Yang HL, Xia B, Tian C. Extracellular vesicles derived from T-cell acute lymphoblastic leukemia inhibit osteogenic differentiation of bone marrow mesenchymal stem cells via miR-34a-5p. Endocr J. 2021;68(10):1197\u2013208.","journal-title":"Endocr J"},{"issue":"Suppl 1","key":"4464_CR29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134649","volume":"136","author":"MWE Smeets","year":"2020","unstructured":"Smeets MWE, Stalpers F, Vermeeren MMP, Hoogkamer AQ, Nierkens S, Ven CVD, et al. B-Cell precursor acute lymphoblastic leukemia instructs mesenchymal stromal cells to alter interferon-related gene expression and cyto\/chemokine secretion. Blood. 2020;136(Suppl 1):4.","journal-title":"Blood"},{"key":"4464_CR30","doi-asserted-by":"crossref","first-page":"634937","DOI":"10.3389\/fimmu.2021.634937","volume":"12","author":"M Sajid","year":"2021","unstructured":"Sajid M, Ullah H, Yan K, He M, Feng J, Shereen MA, et al. The functional and antiviral activity of interferon alpha-inducible IFI6 against hepatitis B virus replication and gene expression. Front Immunol. 2021;12:634937.","journal-title":"Front Immunol"},{"issue":"8","key":"4464_CR31","first-page":"e132743","volume":"10","author":"Y Qi","year":"2015","unstructured":"Qi Y, Li Y, Zhang Y, Zhang L, Wang Z, Zhang X, et al. IFI6 inhibits apoptosis via mitochondrial-dependent pathway in dengue Virus 2 infected vascular endothelial cells. PLoS ONE. 2015;10(8):e132743.","journal-title":"PLoS ONE"},{"issue":"1","key":"4464_CR32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12967-020-02698-x","volume":"19","author":"X Zhao","year":"2021","unstructured":"Zhao X, Zhang L, Wang J, Zhang M, Song Z, Ni B, et al. Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. J Transl Med. 2021;19(1):35.","journal-title":"J Transl Med"},{"key":"4464_CR33","first-page":"8","volume":"2017","author":"J Rodr\u00edguez-Carrio","year":"2007","unstructured":"Rodr\u00edguez-Carrio J, Alperi-L\u00f3pez M, L\u00f3pez P, Ballina-Garc\u00eda FJ, Su\u00e1rez A. Heterogeneity of the type I interferon signature in rheumatoid arthritis: a potential limitation for its use as a clinical biomarker. Front Immunol. 2007;2017:8.","journal-title":"Front Immunol"},{"issue":"17","key":"4464_CR34","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/onc.2011.393","volume":"31","author":"V Cheriyath","year":"2012","unstructured":"Cheriyath V, Kuhns MA, Jacobs BS, Evangelista P, Elson P, Downs-Kelly E, et al. G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene. 2012;31(17):2222\u201336.","journal-title":"Oncogene"},{"key":"4464_CR35","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3389\/fgene.2020.00819","volume":"11","author":"C Hua","year":"2020","unstructured":"Hua C, Zhu J, Zhang B, Sun S, Song Y, van der Veen S, et al. Digital RNA sequencing of human epidermal keratinocytes carrying human papillomavirus type 16 E7. Front Genet. 2020;11:819.","journal-title":"Front Genet"},{"issue":"1","key":"4464_CR36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12935-021-02142-0","volume":"21","author":"X Yin","year":"2021","unstructured":"Yin X, Yang J, Chen J, Ni R, Zhou Y, Song H, et al. LncRNA CTD-3252C9.4 modulates pancreatic cancer cell survival and apoptosis through regulating IFI6 transcription. Cancer Cell Int. 2021;21(1):433.","journal-title":"Cancer Cell Int"},{"key":"4464_CR37","doi-asserted-by":"crossref","first-page":"e16432","DOI":"10.7554\/eLife.16432","volume":"5","author":"R Gupta","year":"2016","unstructured":"Gupta R, Forloni M, Bisserier M, Dogra SK, Yang Q, Wajapeyee N. Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth. eLife. 2016;5:e16432.","journal-title":"eLife"},{"key":"4464_CR38","first-page":"5548918","volume":"2021","author":"Y He","year":"2021","unstructured":"He Y, Cao Y, Wang X, Jisiguleng W, Tao M, Liu J, et al. Identification of hub genes to regulate breast cancer spinal metastases by bioinformatics analyses. Comput Math Methods Med. 2021;2021:5548918.","journal-title":"Comput Math Methods Med"},{"issue":"10","key":"4464_CR39","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1172\/JCI31122","volume":"117","author":"V Cheriyath","year":"2007","unstructured":"Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest. 2007;117(10):3107\u201317.","journal-title":"J Clin Invest"},{"issue":"33","key":"4464_CR40","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.2174\/0929867326666191113113110","volume":"27","author":"P Yang","year":"2020","unstructured":"Yang P, Hu Y, Zhou Q. The CXCL12-CXCR4 signaling axis plays a key role in cancer metastasis and is a potential target for developing novel therapeutics against metastatic cancer. Curr Med Chem. 2020;27(33):5543\u201361.","journal-title":"Curr Med Chem"},{"issue":"9","key":"4464_CR41","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00018-014-1830-x","volume":"72","author":"PA de Lourdes","year":"2015","unstructured":"de Lourdes PA, Amarante MK, Guembarovski RL, de Oliveira CE, Watanabe MA. CXCL12\/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target. Cell Mol Life Sci. 2015;72(9):1715\u201323.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4464_CR42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3324\/haematol.2011.052779","volume":"97","author":"B Stamatopoulos","year":"2012","unstructured":"Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 2012;97(4):608\u201315.","journal-title":"Haematologica"},{"issue":"3","key":"4464_CR43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.exphem.2012.11.004","volume":"41","author":"R Welschinger","year":"2013","unstructured":"Welschinger R, Liedtke F, Basnett J, Dela Pena A, Juarez JG, Bradstock KF, et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2013;41(3):293\u2013302.","journal-title":"Exp Hematol"},{"key":"4464_CR44","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.2147\/OTT.S249425","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang S, Wang X, Liu S, Zhang S, Wei X, Song Y, et al. The CXCR4 antagonist, AMD3100, reverses mesenchymal stem cell-mediated drug resistance in relapsed\/refractory acute lymphoblastic leukemia. Onco Targets Ther. 2020;13:6583\u201391.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"4464_CR45","first-page":"1594","volume":"25","author":"W Chang","year":"2020","unstructured":"Chang W, Wang J, Xiao Y. Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK\/ERK and PI3K\/AKT signalling pathways. J BUON. 2020;25(3):1594\u20139.","journal-title":"J BUON"},{"key":"4464_CR46","doi-asserted-by":"crossref","first-page":"144726","DOI":"10.1016\/j.gene.2020.144726","volume":"751","author":"X Liu","year":"2020","unstructured":"Liu X, Zhou C, Li Y, Deng Y, Lu W, Li J. Upregulation of circ-0000745 in acute lymphoblastic leukemia enhanced cell proliferation by activating ERK pathway. Gene. 2020;751:144726.","journal-title":"Gene"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04464-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04464-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T02:14:57Z","timestamp":1700446497000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04464-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4464"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04464-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained in accordance with the Declaration of Helsinki. All experiments with primary samples were approved by the Ethics Committee of the Affiliated Hospital of Guizhou Medical University. The informed consent has been signed by all patients before their samples were acquired. The animal procedures were approved by the Animal Care Welfare Committee of Guizhou Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author(s) declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"593"}}